Related Experiment Video
Updated: Jul 4, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
PPARgamma and MEK Interactions in Cancer
Elke Burgermeister1, Rony Seger
1Department of Medicine II, Klinikum Rechts der Isar, Technical University, 81675 Munich, Germany.
PPAR Research
|July 4, 2008
Summary
Peroxisome proliferator-activated receptor-gamma (PPARgamma) and its ligands have dual roles in cancer. Crosstalk with MEK-ERK signaling influences these effects, offering potential cancer therapy targets.
Area of Science:
- Molecular biology
- Cell signaling
- Cancer research
Background:
- Peroxisome proliferator-activated receptor-gamma (PPARgamma) is crucial for cell fate, metabolism, and immunity.
- PPARgamma ligands, like rosiglitazone and pioglitazone, treat type-2 diabetes and show potential for inflammatory diseases and cancer.
- PPARgamma's role in cancer is complex, acting as both a tumor suppressor and promoter.
Purpose of the Study:
- To review the molecular mechanisms of crosstalk between PPARgamma and mitogen-activated protein kinase (MAPK) cascades.
- To discuss the physiological implications of this signaling crosstalk in cancer.
- To explore the potential of targeting the PPARgamma-MEK-ERK pathway for cancer therapy.
Main Methods:
- Literature review of studies on PPARgamma signaling and MAPK pathways.
- Analysis of molecular mechanisms involving PPARgamma phosphorylation and compartmentalization.
- Examination of ligand-dependent and independent activation of signaling cascades.
Main Results:
- PPARgamma activity is modulated by MAPK-mediated phosphorylation and nucleocytoplasmic transport.
- PPARgamma ligands can activate the MEK-ERK cascade via non-genomic pathways.
- The interplay between PPARgamma and MEK-ERK signaling contributes to its dual role in cancer modulation.
Conclusions:
- The crosstalk between PPARgamma and MEK-ERK signaling is a key determinant of PPARgamma's effect on tumors.
- Understanding these molecular mechanisms is vital for developing targeted cancer therapies.
- Targeting the PPARgamma-MEK-ERK pathway presents a promising avenue for novel cancer treatment strategies.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...